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SUMMARY
Iron deﬁciency is common and can be effectively treated
with parenteral iron infusion. We report a case of an
iron-deﬁcient and vitamin D-deﬁcient woman who
developed severe symptomatic hypophosphataemia
following intravenous ferric carboxymaltose
administration. We stress the need of increased
awareness of this potential complication among
physicians. Patients should be informed of this
complication and instructed to report for follow-up if
they experience new musculoskeletal symptoms or
worsening of tiredness. As severe hypophosphataemia is
usually symptomatic, we recommend screening
symptomatic patients for this complication. Recognising
and treating the possible exacerbating factors, especially
vitamin D deﬁciency, might be a simple measure to
mitigate this complication.
BACKGROUND
There are many indications for parenteral iron
administration such as chronic kidney disease, heart
failure, inﬂammatory bowel disease and postbaria-
tric surgery. Iron deﬁciency with or without
anaemia is, however, most prevalent in the other-
wise healthy menstruating women. The parenteral
route is also preferred in these patients since oral
iron has low bioavailability and can cause gastro-
intestinal side effects.1
Ferric carboxymaltose is one of the most com-
monly used parenteral iron formulations because of
the ease of administration of a relatively large dose
in a single infusion (up to 1 g of elemental iron)
and fewer allergic side effects when compared with
older iron preparations.
Severe hypophosphataemia has been described as
a potential complication of certain parenteral iron
formulations (such as ferric carboxymaltose, sac-
charated ferric oxide).2–11 In 2008, FDA reported
that 2.1% of patients treated with ferric carboxy-
maltose developed hypophosphataemia, but severe
hypophosphataemia was rare. Mild hypophospha-
taemia is mentioned as a common complication in
product labelling information of ferric carboxymal-
tose, but not widely acknowledged.12 Recently,
Schaefer et al13 revealed high prevalence of severe
hypophosphataemia (32.1%) after treatment of
iron deﬁciency with high-dose intravenous ferric
carboxymaltose in a patient population with gastro-
intestinal disorders.
CASE PRESENTATION
A woman of Mexican origin aged 38 years was
referred to our clinic for the evaluation of
tiredness, diffuse muscle pain and weakness for the
past year. She was advised to get her adrenal func-
tion checked in a consultation in her own country,
which is why she speciﬁcally asked for a referral to
an endocrinology clinic. She had no family history
of bone or mineral metabolism disorders. She grew
and developed normally as a child, and denied
alcohol consumption and smoking. Her general
physician detected iron deﬁciency anaemia 7 weeks
before consultation in our clinic; ferritin was
7.8 μg/L (13–150) and haemoglobin 111 g/L (117–
153). At the same time, vitamin B12 was 146 pmol/
L (>220). She received an intramuscular injection
of 1 mg vitamin 12 injection the next day (2 weeks
before the ﬁrst iron administration). Her folate
levels were not measured.
She was treated with parenteral ferric carboxy-
maltose at a dose of 500 mg which was given
twice (4, respectively, 3 weeks before presentation
to our clinic). The cause of her iron deﬁciency
anaemia was heavy menstrual bleeding, for which
her gynaecologist inserted a levonorgestrel-
containing IUD before her ﬁrst presentation in our
clinic.
Her history revealed intravenous iron administra-
tion 1 year before. Interestingly, she reported no
symptom relief after iron administration recently as
well as in the past. She reported an exacerbation of
her muscle pain and weakness after her previous
iron infusion. Her complaints and symptoms were
believed to be manifestation of depression.
Physical examination ﬁndings were as follows:
height 145 cm (within her midparental range),
weight 54 kg, BMI 25.8 kg/m2, blood pressure 125/
80 mm Hg, pulse 80/min with normal cardiac and
pulmonary auscultation ﬁndings. The abdominal
examination revealed slight tenderness in the right
midabdomen with normal bowel sounds. Her
overall appearance did not indicate any bone or
facial deformity.
INVESTIGATIONS
Laboratory tests on presentation (table 1, day 0)
revealed severe hypophosphataemia, 0.23 mmol/L
(0.87–1.45), a slightly low albumin-adjusted
calcium, 1.99 mmol/L (2.09–2.54) and a low
25-hydroxy-vitamin D, 12 μg/L (recommended
value >20).
Coeliac screening was negative. Liver enzymes
were not elevated. Serum ferritin was 662 μg/L
(reﬂecting the recent iron infusions). Haemoglobin
was normalised (124 g/L). Creatinine was in the
low normal range, 42 μmol/L (44–80). Morning
cortisol was 324 nmol/L, which together with
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normal serum sodium and potassium values and lack of speciﬁc
symptoms (no hyperpigmentation and weight loss) made
primary adrenal insufﬁciency an unlikely diagnosis. There was
no history of glucocorticoid use in the past.
Along with conﬁrming hypophosphataemia (day 2), we inves-
tigated its cause. We measured the concentration of phosphate
and creatinine in a fasting spot urine sample to evaluate renal
phosphate transport by calculating TmP/GFR. This value corre-
sponds to the theoretical lower limit of plasma phosphate below
which all ﬁltered phosphate would be absorbed (normal range,
0.80–1.35 mmol/L).
TmP=GFR inmmol=L ¼ Pp  [Up  Pcrea =Ucrea]
where PP, UP, PCrea and UCrea refer to the plasma and urinary
concentration of phosphate and creatinine, respectively.14
A low value indicates renal phosphate wasting. In our patient,
it was 0.21 mmol/L.
Intact parathyroid hormone (PTH) was slightly increased,
69.5 ng/L (15–65), presumably as an adaptive response to
vitamin D deﬁciency. Her calcium was low due to vitamin D
deﬁciency. Alkaline phosphatase and its bone-speciﬁc isoform
were not elevated, suggesting that her hypophosphataemia was
probably of recent onset and did not result in a serious mineral-
isation disorder.
The absence of albuminuria and glucosuria ruled out a
generalised proximal tubular disorder (Fanconi syndrome).
1,25-dihydroxyvitamin D was low, 23.8 ng/L (26.1–95), which
in the face of hypophosphataemia suggested excessive ﬁbroblast
growth factor 23 (FGF23) to be the cause of increased renal
phosphate excretion since FGF23 promotes renal phosphate
loss and impairs 1-α-hydroxylation of vitamin D.
TREATMENT
We started vitamin D replacement with 2000 IU/day for 4 weeks
and continued with 1000 IU/day thereafter. She was also treated
with calcitriol 0.25 μg two times per day for a total duration of
36 days.
OUTCOME AND FOLLOW-UP
Our patient reported relief of her tiredness, muscle pain and
weakness on vitamin D replacement and calcitriol within 2 days
of starting the treatment. Phosphate values normalised under
treatment and remained normal 1 week after stopping calcitriol
(table 1). At the same time 1,25-dihydroxyvitamin D was high
normal. Vitamin D replacement was continued.
25-hydroxyvitamin D levels normalised in the follow-up
3 months later. Her monthly bleeding reduced after insertion of
levonorgestrel-containing IUD. Haemoglobin and ferritin values
remained stable in the follow-up 3 months later.
DISCUSSION
In our case, hypophosphataemia was severe, prolonged and
symptomatic. Low TmP/GFR conﬁrmed that hypophosphatae-
mia was due to renal phosphate wasting which can occur in
proximal tubular disorders, in hyperparathyroidism and in dis-
orders of FGF23 excess. We excluded Fanconi syndrome.
Secondary hyperparathyroidism (calcium was low normal)
causes only mild renal phosphate loss and is associated with
high normal 1,25-dihydroxyvitamin D levels. FGF23 excess
appeared to be the most likely cause of renal phosphate wasting.
Disorders of FGF23 excess can be either acute or chronic.
Chronic FGF23 excess as in tumour-induced osteomalacia is
usually associated with mineralisation disorder reﬂected by
increased bone-speciﬁc alkaline phosphatase.15 This was not the
case in our patient.
Our patient received ferric carboxymaltose infusion twice,
making increased FGF23 activity the most likely cause of hypo-
phosphataemia as supported by renal phosphate wasting and
low 1,25-dihydroxyvitamin D.10 15
Hypovitaminosis D was detected but not treated by her phys-
ician before iron administration, making baseline hypophospha-
taemia (and secondary hyperparathyroidism) as a probable
additional risk factor. However, phosphate values were not
measured.
Increased erythropoiesis after correction of iron deﬁciency
could also result in mild hypophosphataemia by increased cellu-
lar uptake of phosphate, but this would not explain increased
renal phosphate loss.11
FGF23 is a phosphatonin secreted by osteocytes leading to
phosphate wasting through inhibition of Na+-dependent phos-
phate cotransporters in the proximal renal tubules. Iron deﬁ-
ciency per se increases FGF23 transcription as well as its
degradation. Administration of ferric carboxymaltose inhibits
FGF23 degradation and thereby increases the biologically active
FGF23, which then can cause hypophosphataemia.2–11 Owing
to the complex interplay of different FGF23 forms and their
processing in iron deﬁciency, measuring FGF23 values is not
recommended in clinical practice. Furthermore, FGF23 assays
are not routinely available and expensive. TmP/GFR and
1,25-dihydroxyvitamin D are simple tests providing useful infor-
mation about the mechanism of hypophosphataemia in severe
cases.
The nadir of serum phosphate is usually reached 2 weeks
after administration of intravenous iron. The median time to
normalisation of phosphate after a single iron infusion is
84 days, but may be prolonged after repetitive iron infusions.13
Vitamin D deﬁciency should be screened and corrected in all
patients. Calcitriol cannot correct FGF23 excess, but its replace-
ment plays an important role as it helps to increase intestinal
phosphate absorption, attenuates secondary hyperparathyroid-
ism and thereby corrects and shortens the duration of hypopho-
sphataemia. 1,25-dihydroxyvitamin D was low at baseline
reﬂecting the suppressive effect of FGF23 on 1-α-hydroxylation
of vitamin D. We also chose calcitriol in our patient since phos-
phate and calcium were low (and PTH elevated presumably due
to coexisting vitamin D deﬁciency). Also in patients with
normal vitamin D status and normal calcium values, calcitriol
can be considered as 1,25-dihydroxyvitamin D levels are low
Table 1 Evolution of laboratory values since presentation in our
clinic
Days since presentation 0 2 25 51 101
Calcium, albumin-corrected
(2.09–2.54 mmol/L)
1.99 2.05 2.22 2.21 2.15
Phosphate (0.87–1.45 mmol/L) 0.23 0.30 0.93 1.06 1.17
Creatinine (44–80 mmol/L) 42 40 52 43 45
PTH (15–65 ng/L) 52.7 69.5 46.5 46.3
25-hydroxyvitamin D (>20 mg/L) 12 28
1,25-dihydroxy-vitamin D (26.1–95 ng/L) 23.8 74.8 71.8
TmP/GFR (0.8–1.35 mmol/L) 0.21 0.83 0.91
The patient presented with hypophosphataemia on day 0 (which was 3 weeks
following the last intravenous administration of ferric carboxymaltose), and
hypophosphataemia was confirmed on day 2, along with the finding of increased
renal phosphate loss and a low calcitriol.
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due to excessive FGF23 activity. As our patient responded well
to calcitriol, we did not give phosphate supplementation.
Additionally, large amount of phosphate needed to correct
hypophosphataemia in renal phosphate wasting often cause
gastrointestinal side effects.
Considering the expanding use of intravenous iron, we hope
our case contributes to the awareness of general physicians as
well as specialists for this potential complication. Patients should
be informed and instructed to report for follow-up if they
experience new musculoskeletal symptoms or worsening of
tiredness.
Recently, Schaefer et al13 found signiﬁcantly less hypopho-
sphataemia with ferric isomaltoside (not yet available in our
country) compared with ferric carboxymaltose. This iron form
might be preferred in patients prone to hypophosphataemia.
However, risk of hypersensitivity reactions is higher with ferric
isomaltoside. The possibility of different side effects needs to be
carefully considered and balanced.16
Patient’s perspective
I always wanted to know the reason for my tiredness and
muscle pain, which actually worsened after getting iron
infusion. I never felt any depression, which was initially thought
to be the cause of my symptoms. I am happy to know the
cause of my symptoms now. The treatment immediately worked
as an energy boost. Now I work and do daily activities as a
normal person.
Learning points
▸ Clinicians prescribing ferric carboxymaltose should be aware
of the potential complication of hypophosphataemia.
▸ Serum phosphate levels should be measured at least in
symptomatic patients after administration of iron infusion.
Cause of severe hypophosphataemia can be determined by
estimating TmP/GFR and 1,25-dihydroxyvitamin D.
▸ Correction of coexisting vitamin D deﬁciency could be a
simple measure to mitigate hypophosphataemia.
▸ Hypophosphataemia, if symptomatic and severe, can be
treated with calcitriol and possibly phosphate supplements
until its remission.
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